サンプル依頼リスト カート
  • English
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1764897

欧州の緑内障治療薬市場の予測 (2031年まで) - 地域別分析 (薬剤クラス別、適応症別、販売チャネル別)

Europe Glaucoma Therapeutics Market Forecast to 2031 - Regional Analysis - by Drug Class, Indication, and Distribution Channel

出版日
ページ情報
英文 133 Pages
納期
即納可能 即納可能とは
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.89円
欧州の緑内障治療薬市場の予測 (2031年まで) - 地域別分析 (薬剤クラス別、適応症別、販売チャネル別)
出版日: 2025年04月14日
発行: The Insight Partners
ページ情報: 英文 133 Pages
納期: 即納可能 即納可能とは
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

欧州の緑内障治療薬市場は、2023年に15億2,983万米ドルと評価され、2031年には19億3,078万米ドルに達すると予測され、2023年から2031年までのCAGRは3.0%と推定されます。

製品上市、提携、買収の増加が欧州緑内障治療薬市場を活性化

緑内障治療薬メーカーは、市場での存在感を示すために、戦略的提携、地理的拡大、パートナーシップ、合併・買収、製品・サービスの発売などの戦略を実施しています。

2024年3月、革新的な眼ドラッグデリバリー技術を専門とするMediPrint Ophthalmics社は、第2b相緑内障SIGHT-2試験の成功裏の終了を発表しました。

2023年12月、米国食品医薬品局（FDA）は、高眼圧症（OHT）または開放隅角緑内障（OAG）患者の眼圧下降を適応症とするプロスタグランジンアナログ製剤iDose TR（トラボプロスト膀胱内インプラント）75mcgの新薬承認申請（NDA）をグラウコス社に承認しました。同剤は片眼単回投与が承認されています。

2022年11月、アルコンはAerie Pharmaceuticals, Inc.を買収しました。この買収により、アルコンはロックラタン（ネタルスジル・ラタノプロスト点眼液）0.02%/0.005%、ロプレッサ（ネタルスジル点眼液）0.02%、ドライアイ治療薬第3相候補のAR-15512、および複数の前臨床・臨床眼科用医薬品候補のパイプラインを獲得しました。RocklatanとRhopressaは、開放隅角緑内障または高眼圧症患者の眼圧上昇の抑制を適応症とするRho-kinase阻害剤です。この買収により、アルコンは緑内障、網膜および眼表面疾患治療薬を含むポートフォリオを拡大する一歩を踏み出しました。

2022年3月、ジョンソン・エンド・ジョンソンビジョンケア社は、ケトチフェンと呼ばれる抗ヒスタミン剤（レンズ1枚あたり19μg）を配合したコンタクトレンズ、アキュビューセラビジョンの新バリエーションのFDA承認を取得しました。ケトチフェン配合のACUVUE Theravisionは、この種のものとしては初めてで、アレルギー性の目のかゆみを経験するコンタクトレンズユーザーに新しい装用体験を提供するように設計されています。このような製品の発売、提携、買収は緑内障治療薬市場の成長に大きく貢献しています。

欧州の緑内障治療薬市場概要

欧州の緑内障治療薬市場は、ドイツ、フランス、英国、スペイン、イタリア、その他欧州に区分されます。ドイツやイタリアなどの国々は、この地域の市場に大きなシェアを占めており、フランス、英国、スペインなどの国々は、緑内障治療薬市場のプレーヤーに大きな成長機会をもたらすと考えられます。欧州の緑内障治療薬市場の成長は、高齢化人口の増加に伴う緑内障症例の増加に起因しています。ドイツでは緑内障が広く発生しています。Sabel Vision Restoration Center（SAVIR）によると、この国では約50万人が緑内障に罹患しています。しかし、専門家は、報告されていない症例があるため、実際の数はもっと多いだろうと推定しています。緑内障に罹患した人の10％近くが最終的に深刻な視力障害を経験するが、完全な失明に至る人はほとんどいないです。連邦統計局（Destatis）によると、ドイツでは2021年末までに67歳以上の高齢者が1,620万人に達し、2060年には2,160万人に増加すると予測されています。緑内障をはじめとする眼疾患の開発確率は、加齢とともに高くなると考えられます。したがって、老年人口の急増による緑内障の著しい有病率が、ドイツ全土における緑内障治療薬の需要を促進しています。

欧州の緑内障治療薬市場の収益と2031年までの予測（金額）

欧州の緑内障治療薬市場のセグメンテーション

欧州の緑内障治療薬市場は、薬剤クラス別・適応症別・流通チャネル別・国別に分類されます。

欧州の緑内障治療薬市場は薬剤クラス別に、β遮断薬、αアドレナリン作動薬、プロスタグランジン類似体、炭酸脱水酵素阻害薬、併用薬、その他に区分されます。2023年には、プロスタグランジン類似体セグメントが最大の市場シェアを占めています。

適応症の観点から、欧州緑内障治療薬市場は開放隅角緑内障、閉塞隅角緑内障、その他に分類されます。開放隅角緑内障セグメントが2023年に最大の市場シェアを占めました。

流通チャネル別では、欧州緑内障治療薬市場は病院薬局、小売薬局、オンライン薬局に分類されます。病院薬局セグメントが2023年に最大の市場シェアを占めました。

国別では、欧州緑内障治療薬市場はドイツ、フランス、イタリア、英国、スペイン、その他欧州に区分されます。2023年の欧州緑内障治療薬市場シェアはドイツが独占。

Alcon AG、AbbVie Inc、Bausch &Lomb Inc, LLC、Viatris Inc、Novartis AG、Sun Pharmaceutical Industries Ltd、Teva Pharmaceuticals Industries Ltd、Thea Pharma Inc、Santen Pharmaceutical Co., Ltd.は、欧州の緑内障治療薬市場で事業を展開する主要企業です。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

  • 主要洞察
  • 市場の魅力

第3章 分析手法

  • 二次調査
  • 一次調査
    • 仮説の策定
    • マクロ経済要因分析
    • 基礎数値の開発
    • データの三角測量
    • 国レベルのデータ

第4章 欧州の緑内障治療薬市場：主な市場力学

  • 緑内障治療薬市場：主な市場力学
  • 市場促進要因
    • 緑内障罹患率の増加
    • 製品上市、提携、買収の増加
  • 市場抑制要因
    • 服薬コンプライアンスの問題
  • 市場機会
    • ウェアラブル技術の開発
  • 今後の動向
    • 新しい薬剤送達法の開発
  • 促進要因と抑制要因の影響

第5章 緑内障治療薬市場：欧州市場の分析

  • 緑内障治療薬市場の収益 (2021～2031年)
  • 緑内障治療薬市場の予測・分析

第6章 欧州の緑内障治療薬市場の分析：薬剤クラス別

  • β遮断薬
  • αアドレナリン作動薬
  • プロスタグランジン類縁体
  • 炭酸脱水酵素阻害薬
  • 配合剤
  • その他

第7章 欧州の緑内障治療薬市場の分析：適応症別

  • 開放隅角緑内障
  • 閉塞隅角緑内障
  • その他

第8章 欧州緑内障治療薬市場の分析：流通チャネル別

  • 病院薬局
  • 小売薬局
  • オンライン薬局

第9章 欧州緑内障治療薬市場：国別分析

  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • その他欧州

第10章 緑内障治療薬市場：業界情勢

  • 緑内障治療薬市場における成長戦略
  • 有機的成長戦略
  • 無機的成長戦略

第11章 企業プロファイル

  • Alcon AG
  • AbbVie Inc
  • Bausch & Lomb Inc
  • Viatris Inc
  • Novartis AG
  • Sun Pharmaceutical Industries Ltd
  • Teva Pharmaceutical Industries Ltd
  • Thea Pharma Inc
  • Santen Pharmaceutical Co., Ltd.

第12章 付録

図表

List Of Tables

  • Table 1. Europe Glaucoma Therapeutics Market Segmentation
  • Table 2. Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Table 3. Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Class
  • Table 4. Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Indication
  • Table 5. Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Distribution Channel
  • Table 6. Europe: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Country
  • Table 7. Germany: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Class
  • Table 8. Germany: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Indication
  • Table 9. Germany: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Distribution Channel
  • Table 10. France: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Class
  • Table 11. France: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Indication
  • Table 12. France: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Distribution Channel
  • Table 13. United Kingdom: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Class
  • Table 14. United Kingdom: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Indication
  • Table 15. United Kingdom: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Distribution Channel
  • Table 16. Italy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Class
  • Table 17. Italy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Indication
  • Table 18. Italy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Distribution Channel
  • Table 19. Spain: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Class
  • Table 20. Spain: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Indication
  • Table 21. Spain: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Distribution Channel
  • Table 22. Rest of Europe: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Class
  • Table 23. Rest of Europe: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Indication
  • Table 24. Rest of Europe: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Distribution Channel
  • Table 25. Recent Organic Growth Strategies in Glaucoma Therapeutics Market
  • Table 26. Recent Inorganic Growth Strategies in the Glaucoma Therapeutics Market
  • Table 27. Glossary of Terms

List Of Figures

  • Figure 1. Europe Glaucoma Therapeutics Market Segmentation, by Country
  • Figure 2. Impact Analysis of Drivers and Restraints
  • Figure 3. Glaucoma Therapeutics Market Revenue (US$ Million), 2021-2031
  • Figure 4. Glaucoma Therapeutics Market Share (%) - by Drug Class (2023 and 2031)
  • Figure 5. Beta Blockers: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 6. Alpha Adrenergic Agonists: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 7. Prostaglandins Analogues: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 8. Carbonic Anhydrase Inhibitors: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 9. Combination Drugs: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 10. Others: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 11. Glaucoma Therapeutics Market Share (%) - by Indication (2023 and 2031)
  • Figure 12. Open Angle Glaucoma: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 13. Angle Closure Glaucoma: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 14. Others: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 15. Glaucoma Therapeutics Market Share (%) - by Distribution Channel (2023 and 2031)
  • Figure 16. Hospital Pharmacy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 17. Retail Pharmacy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 18. Online Pharmacy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 19. Europe Glaucoma Therapeutics Market, by Key Country - Revenue (2023) (US$ Million)
  • Figure 20. Europe: Glaucoma Therapeutics Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 21. Germany: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 22. France: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 23. United Kingdom: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 24. Italy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 25. Spain: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 26. Rest of Europe: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 27. Growth Strategies in Glaucoma Therapeutics Market
目次
Product Code: BMIRE00031611

The Europe glaucoma therapeutics market was valued at US$ 1,529.83 million in 2023 and is expected to reach US$ 1,930.78 million by 2031; it is estimated to register a CAGR of 3.0% from 2023 to 2031.

Increasing Number of Product Launches, Collaborations, and Acquisitions Fuels Europe Glaucoma Therapeutics Market

Glaucoma therapeutics manufacturers are implementing strategies such as strategic alliances, geographic expansions, partnerships, mergers & acquisitions, and product/service launches to mark their presence in the market.

In March 2024, MediPrint Ophthalmics, a company that specializes in innovative ocular drug delivery technologies, announced the successful completion of its Phase 2b Glaucoma SIGHT-2 study.

In December 2023, the US Food and Drug Administration (FDA) approved Glaukos Corporation's New Drug Application (NDA) for iDose TR (travoprost intracameral implant) 75 mcg, a prostaglandin analog indicated for the reduction of IOP in patients with ocular hypertension (OHT) or open-angle glaucoma (OAG). The drug was approved for a single administration per eye.

In November 2022, Alcon acquired Aerie Pharmaceuticals, Inc. Through the transaction, Alcon acquired Rocklatan (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%; Rhopressa (netarsudil ophthalmic solution) 0.02%; AR-15512, a Phase 3 product candidate for dry eye disease; and a pipeline of several preclinical and clinical ophthalmic pharmaceutical product candidates. Rocklatan and Rhopressa are Rho-kinase inhibitors indicated for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension. With this acquisition, Alcon takes a step forward to broaden its portfolio with the inclusion of glaucoma, and retinal and ocular surface disease therapeutics.

In March 2022, Johnson & Johnson Vision Care, Inc. received FDA approval for its new ACUVUE Theravision variant, a type of contact lens containing an antihistamine called ketotifen (19 µg per lens). ACUVUE Theravision with Ketotifen is the first of its kind and is designed to provide a new wearing experience for contact lens users, experiencing allergic eye itch. Such product launches, collaborations, and acquisitions contribute significantly to the growth of the glaucoma therapeutics market.

Europe Glaucoma Therapeutics Market Overview

The Europe glaucoma therapeutics market is segmented into Germany, France, the UK, Spain, Italy, and the Rest of Europe. Countries such as Germany and Italy contribute significant shares to the market in this region, and countries such as France, the UK, and Spain are likely to present significant growth opportunities for glaucoma therapeutics market players. The Europe glaucoma therapeutics market growth is ascribed to the rising number of glaucoma cases with the increasing aging population. Germany records a widespread occurrence of glaucoma. According to Sabel Vision Restoration Center (SAVIR), approximately half a million people are affected by glaucoma in this country. However, experts estimate that the actual number may be much higher due to unreported cases. Nearly 10% of all individuals suffering from glaucoma eventually experience serious vision impairments; nonetheless, almost none is likely to attain complete blindness. As per the Federal Statistical Office (Destatis), 16.2 million people in Germany were aged 67 and above by the end of 2021, and the number is projected to rise to 21.6 million by 2060. The probability of developing glaucoma and other eye diseases is likely to increase with aging. Thus, a significant prevalence of glaucoma due to the surging geriatric population propels the demand for glaucoma therapeutics across Germany.

Europe Glaucoma Therapeutics Market Revenue and Forecast to 2031 (US$ Million)

Europe Glaucoma Therapeutics Market Segmentation

The Europe glaucoma therapeutics market is categorized into drug class, indication, distribution channel, and country.

Based on drug class, the Europe glaucoma therapeutics market is segmented into beta blockers, alpha adrenergic agonists, prostaglandins analogues, carbonic anhydrase inhibitors, combination drugs, and others. The prostaglandins analogues segment held the largest market share in 2023.

In terms of indication, the Europe glaucoma therapeutics market is categorized into open angle glaucoma, angle closure glaucoma, and others. The open angle glaucoma segment held the largest market share in 2023.

By distribution channel, the Europe glaucoma therapeutics market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment held the largest market share in 2023.

By country, the Europe glaucoma therapeutics market is segmented into Germany, France, Italy, the UK, Spain, and the Rest of Europe. Germany dominated the Europe glaucoma therapeutics market share in 2023.

Alcon AG, AbbVie Inc, Bausch & Lomb Inc, LLC, Viatris Inc, Novartis AG, Sun Pharmaceutical Industries Ltd, Teva Pharmaceuticals Industries Ltd, Thea Pharma Inc, and Santen Pharmaceutical Co., Ltd. are among the leading companies operating in the Europe glaucoma therapeutics market.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 Market Attractiveness

3. Research Methodology

  • 3.1 Secondary Research
  • 3.2 Primary Research
    • 3.2.1 Hypothesis formulation:
    • 3.2.2 Macro-economic factor analysis:
    • 3.2.3 Developing base number:
    • 3.2.4 Data Triangulation:
    • 3.2.5 Country level data:

4. Europe Glaucoma Therapeutics Market - Key Market Dynamics

  • 4.1 Glaucoma Therapeutics Market - Key Market Dynamics
  • 4.2 Market Drivers
    • 4.2.1 Mounting Incidence of Glaucoma Disease
    • 4.2.2 Increasing Number of Product Launches, Collaborations, and Acquisitions
  • 4.3 Market Restraints
    • 4.3.1 Medication Regimen Compliance Issues
  • 4.4 Market Opportunities
    • 4.4.1 Development of Wearable Technologies
  • 4.5 Future Trends
    • 4.5.1 Development of Novel Drug Delivery Methods
  • 4.6 Impact of Drivers and Restraints:

5. Glaucoma Therapeutics Market - Europe Analysis

  • 5.1 Glaucoma Therapeutics Market Revenue (US$ Million), 2021-2031
  • 5.2 Glaucoma Therapeutics Market Forecast Analysis

6. Europe Glaucoma Therapeutics Market Analysis - by Drug Class

  • 6.1 Beta Blockers
    • 6.1.1 Overview
    • 6.1.2 Beta Blockers: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • 6.2 Alpha Adrenergic Agonists
    • 6.2.1 Overview
    • 6.2.2 Alpha Adrenergic Agonists: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • 6.3 Prostaglandins Analogues
    • 6.3.1 Overview
    • 6.3.2 Prostaglandins Analogues: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • 6.4 Carbonic Anhydrase Inhibitors
    • 6.4.1 Overview
    • 6.4.2 Carbonic Anhydrase Inhibitors: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • 6.5 Combination Drugs
    • 6.5.1 Overview
    • 6.5.2 Combination Drugs: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • 6.6 Others
    • 6.6.1 Overview
    • 6.6.2 Others: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)

7. Europe Glaucoma Therapeutics Market Analysis - by Indication

  • 7.1 Open Angle Glaucoma
    • 7.1.1 Overview
    • 7.1.2 Open Angle Glaucoma: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.2 Angle Closure Glaucoma
    • 7.2.1 Overview
    • 7.2.2 Angle Closure Glaucoma: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.3 Others
    • 7.3.1 Overview
    • 7.3.2 Others: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)

8. Europe Glaucoma Therapeutics Market Analysis - by Distribution Channel

  • 8.1 Hospital Pharmacy
    • 8.1.1 Overview
    • 8.1.2 Hospital Pharmacy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.2 Retail Pharmacy
    • 8.2.1 Overview
    • 8.2.2 Retail Pharmacy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.3 Online Pharmacy
    • 8.3.1 Overview
    • 8.3.2 Online Pharmacy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)

9. Europe Glaucoma Therapeutics Market - Country Analysis

  • 9.1 Europe
    • 9.1.1 Europe: Glaucoma Therapeutics Market Breakdown, by Key Country, 2023 and 2031 (%)
      • 9.1.1.1 Europe: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Country
      • 9.1.1.2 Germany: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
        • 9.1.1.2.1 Germany: Glaucoma Therapeutics Market Breakdown, by Drug Class
        • 9.1.1.2.2 Germany: Glaucoma Therapeutics Market Breakdown, by Indication
        • 9.1.1.2.3 Germany: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
      • 9.1.1.3 France: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
        • 9.1.1.3.1 France: Glaucoma Therapeutics Market Breakdown, by Drug Class
        • 9.1.1.3.2 France: Glaucoma Therapeutics Market Breakdown, by Indication
        • 9.1.1.3.3 France: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
      • 9.1.1.4 United Kingdom: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
        • 9.1.1.4.1 United Kingdom: Glaucoma Therapeutics Market Breakdown, by Drug Class
        • 9.1.1.4.2 United Kingdom: Glaucoma Therapeutics Market Breakdown, by Indication
        • 9.1.1.4.3 United Kingdom: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
      • 9.1.1.5 Italy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
        • 9.1.1.5.1 Italy: Glaucoma Therapeutics Market Breakdown, by Drug Class
        • 9.1.1.5.2 Italy: Glaucoma Therapeutics Market Breakdown, by Indication
        • 9.1.1.5.3 Italy: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
      • 9.1.1.6 Spain: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
        • 9.1.1.6.1 Spain: Glaucoma Therapeutics Market Breakdown, by Drug Class
        • 9.1.1.6.2 Spain: Glaucoma Therapeutics Market Breakdown, by Indication
        • 9.1.1.6.3 Spain: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
      • 9.1.1.7 Rest of Europe: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
        • 9.1.1.7.1 Rest of Europe: Glaucoma Therapeutics Market Breakdown, by Drug Class
        • 9.1.1.7.2 Rest of Europe: Glaucoma Therapeutics Market Breakdown, by Indication
        • 9.1.1.7.3 Rest of Europe: Glaucoma Therapeutics Market Breakdown, by Distribution Channel

10. Glaucoma Therapeutics Market - Industry Landscape

  • 10.1 Growth Strategies in Glaucoma Therapeutics Market
  • 10.2 Organic Growth Strategies
    • 10.2.1 Overview
  • 10.3 Inorganic Growth Strategies
    • 10.3.1 Overview

11. Company Profiles

  • 11.1 Alcon AG
    • 11.1.1 Key Facts
    • 11.1.2 Business Description
    • 11.1.3 Products and Services
    • 11.1.4 Financial Overview
    • 11.1.5 SWOT Analysis
    • 11.1.6 Key Developments
  • 11.2 AbbVie Inc
    • 11.2.1 Key Facts
    • 11.2.2 Business Description
    • 11.2.3 Products and Services
    • 11.2.4 Financial Overview
    • 11.2.5 SWOT Analysis
    • 11.2.6 Key Developments
  • 11.3 Bausch & Lomb Inc
    • 11.3.1 Key Facts
    • 11.3.2 Business Description
    • 11.3.3 Products and Services
    • 11.3.4 Financial Overview
    • 11.3.5 SWOT Analysis
    • 11.3.6 Key Developments
  • 11.4 Viatris Inc
    • 11.4.1 Key Facts
    • 11.4.2 Business Description
    • 11.4.3 Products and Services
    • 11.4.4 Financial Overview
    • 11.4.5 SWOT Analysis
    • 11.4.6 Key Developments
  • 11.5 Novartis AG
    • 11.5.1 Key Facts
    • 11.5.2 Business Description
    • 11.5.3 Products and Services
    • 11.5.4 Financial Overview
    • 11.5.5 SWOT Analysis
    • 11.5.6 Key Developments
  • 11.6 Sun Pharmaceutical Industries Ltd
    • 11.6.1 Key Facts
    • 11.6.2 Business Description
    • 11.6.3 Products and Services
    • 11.6.4 Financial Overview
    • 11.6.5 SWOT Analysis
    • 11.6.6 Key Developments
  • 11.7 Teva Pharmaceutical Industries Ltd
    • 11.7.1 Key Facts
    • 11.7.2 Business Description
    • 11.7.3 Products and Services
    • 11.7.4 Financial Overview
    • 11.7.5 SWOT Analysis
    • 11.7.6 Key Developments
  • 11.8 Thea Pharma Inc
    • 11.8.1 Key Facts
    • 11.8.2 Business Description
    • 11.8.3 Products and Services
    • 11.8.4 Financial Overview
    • 11.8.5 SWOT Analysis
    • 11.8.6 Key Developments
  • 11.9 Santen Pharmaceutical Co., Ltd.
    • 11.9.1 Key Facts
    • 11.9.2 Business Description
    • 11.9.3 Products and Services
    • 11.9.4 Financial Overview
    • 11.9.5 SWOT Analysis
    • 11.9.6 Key Developments

12. Appendix

  • 12.1 About The Insight Partners
  • 12.2 Glossary of Terms